KOSDAQ: 321550

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with South Korea’s TiumBio Co., Ltd (KOSDAQ: 321550), securing exclusive development, regulatory filing, and commercialization rights to TiumBio’s drug candidate TU2670 in Greater China, including Hong Kong, Macau, and Taiwan. Agreement DetailsUnder the agreement, Hansoh has the rights…